ZIK1 Inhibitors
Chemical inhibitors of ZIK1 can interfere with various cellular processes by targeting specific signaling pathways and enzymes. Palbociclib, a CDK4/6 inhibitor, arrests the cell cycle in the G1 phase, which is crucial for ZIK1 to perform its role in cell cycle progression. Similarly, PD0332991, another name for Palbociclib, exerts the same influence on CDK4/6, leading to the inhibition of cell cycle progression. MLN8237, targeting Aurora A kinase, disrupts the cell cycle at mitotic entry, which can affect ZIK1's involvement in mitosis. Y-27632, a selective inhibitor of ROCK kinases, alters the dynamics of the actin cytoskeleton and cell adhesion, potentially influencing ZIK1's role in these areas.
Additionally, SB431542 targets the TGF-β signaling pathway by inhibiting ALK5, ALK4, and ALK7 receptors, which can lead to the downregulation of cellular processes such as proliferation and differentiation where ZIK1 plays a part. SP600125's inhibition of JNK signaling can affect transcription factors and genes tied to the cell cycle and apoptosis, subsequently affecting ZIK1's function. LY294002 and Wortmannin, both PI3K inhibitors, disrupt critical pathways for cell growth and survival, which are processes where ZIK1 is likely involved. U0126, inhibiting MEK in the MAPK/ERK pathway, can also affect ZIK1's function related to cell cycle control and differentiation. AZD8055, an mTOR kinase inhibitor, and Rapamycin, which selectively inhibits mTORC1, can disrupt cell growth and metabolism processes regulated by ZIK1. Lastly, Dasatinib, with its broad-spectrum tyrosine kinase inhibition, can disrupt various signaling pathways, including those where ZIK1 may play a regulatory role.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib specifically inhibits CDK4/6, which are crucial for cell cycle progression. Inhibition of CDK4/6 can lead to reduced phosphorylation of the retinoblastoma protein, thereby halting cell cycle progression in the G1 phase. This can result in functional inhibition of ZIK1 by preventing its potential involvement in cell cycle-related processes. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
MLN8237 selectively inhibits Aurora A kinase, which is involved in mitotic entry and spindle assembly. By inhibiting Aurora A kinase, MLN8237 can disrupt the cell cycle at the mitotic entry, potentially inhibiting ZIK1 function in cell cycle regulation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK kinases. By inhibiting ROCK, this compound can alter the actin cytoskeleton dynamics and cell adhesion, which can indirectly inhibit ZIK1's role in cytoskeletal organization and cell migration. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the ALK5, ALK4, and ALK7 receptors, which are part of the TGF-β signaling pathway. Since TGF-β signaling can influence cell proliferation and differentiation, inhibition by SB431542 can indirectly inhibit ZIK1's role in these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 can affect transcription factors and genes involved in cell cycle, apoptosis, and differentiation, which can indirectly inhibit ZIK1's associated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling is important for many cellular processes including cell growth and survival. Inhibition by LY294002 could disrupt these processes, thereby inhibiting ZIK1's role in them. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. This pathway is involved in cell cycle control and differentiation. By inhibiting MEK, U0126 can indirectly inhibit ZIK1's function related to these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor like LY294002, and it also prevents many cellular processes regulated by PI3K signaling. This inhibition can lead to a functional inhibition of ZIK1 by disrupting its potential role in PI3K-regulated pathways. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an inhibitor of mammalian target of rapamycin (mTOR) kinase. Inhibition of mTOR can affect cell growth, proliferation, and survival. Through this inhibition, AZD8055 can indirectly inhibit ZIK1's function in these processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against BCR-ABL and Src family kinases. By inhibiting these kinases, Dasatinib can disrupt multiple signaling pathways involved in cell growth and proliferation, potentially inhibiting ZIK1's function. | ||||||